• Users Online: 260
  • Print this page
  • Email this page
Year : 2022  |  Volume : 16  |  Issue : 1  |  Page : 4-10

Evaluation of clinical efficacy and safety of “Yesaka Liquid” (an ayurvedic liquid formulation) as add-on therapy to oral hypoglycemic agents in type ii diabetes patients

1 Technical Officer, W.H.O., SEARO, New Delhi, India
2 Department of Kayachikitsa for Undergraduate, Postgraduate and Doctoral Courses, Parul Institute of Ayurveda, Parul University, Vadodara, Gujarat, India
3 Department of Cinical Research, Target Institute of Medical Education and Research, Mumbai, India
4 Department of Ayurved Samshodhan Vibhag, Ayurved Sanshodhan Vibhag, Ayurved Seva Sangh, Nashik, Maharashtra, India
5 Department of Ayurveda, Sane Guriji Hospital, Pune, Maharashtra, India
6 Department of Kayachikitsa, Ayurved Seva Sangh, Nashik, Maharashtra, India
7 Department of Sanskrit Samhita Siddhant, D. Y. Patil Deemed to be University School of Ayurveda, Navi Mumbai, Maharashtra, India

Correspondence Address:
Sanjay Tamoli
Target Institute of Medical Education and Research, 402/A, Jaswanti Allied Business Center, Off Link Road, Malad West, Mumbai - 400 064, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/joa.joa_79_21

Rights and Permissions

Introduction: Yesaka Liquid is an Ayurvedic Proprietary formulation containing multiple standardized herbal extracts like Triphala (3 myrobalans), Jamun (Eugenia jambolana), Kutki (Picrorhiza kurrooa), Haridra (Curcuma longa) etc., having potential anti-diabetic and anti-oxidant properties. The evaluation of clinical efficacy and safety of Yesaka Liquid as an Add-on therapy to oral hypoglycemic agents (OHAs) in Type II diabetics was the primary objective of the study. Methods: After obtaining ethical approval and informed consent, at five study sites, 112 patients were randomized in two study groups. The patients in Add-on Group were given Yesaka Liquid along with OHAs while those in the Control Group were asked to continue with the on-going OHA (s) for 90 days. The assessment of efficacy was done by estimation of HbA1c%, quality of life (QOL) on WHO-QOL BREF questionnaire, plasma glucose, serum insulin, symptoms of diabetes mellitus, anthropometric measurements, and changes in homeostatic model assessment for insulin resistance score. The assessment of safety was done by clinical review of all safety parameters and safety-related laboratory parameters. Global assessment of overall safety and tolerability by the physician and patient was also done. Results: Yesaka liquid was found to be effective as add-on therapy to OHAs in type II DM management by controlling the levels of HbA1c and blood sugar. It showed significant effect in reducing various symptoms of type II DM and also improved the QOL of patients. Conclusion: Yesaka Liquid can be recommended as an effective and safe formulation for the management of type II DM as an odd-on therapy.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded211    
    Comments [Add]    

Recommend this journal